Screen Failure

A screen failure is a prospective clinical trial participant who provides informed consent and undergoes the protocol-defined screening process, but is not subsequently randomized or assigned to a study intervention because they fail to meet one or more protocol-defined inclusion or exclusion criteria (or withdraws before that assignment happens). Screen failure is a pre-randomization outcome, not a safety event or a protocol deviation on its own — it is the expected, routine result of an IRB-approved eligibility process doing its job.

Screen failure vs. withdrawal vs. discontinuation

The distinguishing line is randomization (or, in a non-randomized design, formal enrollment/assignment to study intervention):

• Screen failure: consented and screened, never randomized. Recorded in the trial’s screening and enrollment log with a documented reason, but the participant never receives a subject/randomization ID tied to study intervention.
• Withdrawal (pre-randomization): a participant who consents and begins screening but withdraws consent before randomization for reasons unrelated to eligibility (schedule conflict, changed mind, relocation). Many sites log this as a screen failure sub-category rather than a separate status, since the operational effect — no randomization occurs — is the same.
• Withdrawal / discontinuation (post-randomization): a participant who is randomized, receives at least one dose or exposure to study intervention, and later leaves the study or is discontinued (adverse event, lost to follow-up, sponsor-directed). This is not a screen failure. It carries different reporting obligations — safety follow-up, intent-to-treat/safety-population analysis assignment — because the participant was already enrolled in the interventional phase of the trial.

Sites also commonly distinguish a pre-screen failure — a candidate ruled out during an informal phone or chart-review triage, before signing an informed consent form and before ever appearing on the formal screening log — from a true screen failure. Only the latter is typically counted in trial-level screen failure statistics, since it’s the point at which the person became a documented research participant.

Why the screen failure rate matters for enrollment metrics

The screen failure rate (screen failures ÷ total participants screened) is one of the standard recruitment KPIs tracked in a CTMS and reviewed at site initiation and ongoing monitoring visits, alongside screen-to-randomization ratio and time-to-enrollment. It is not just an administrative tally:

• A high screen failure rate against a specific criterion (e.g., a narrow lab-value window or a comorbidity exclusion) is one of the signals sponsors and CROs use to judge whether eligibility criteria are appropriately calibrated to the real target population, versus unnecessarily restrictive — a finding that can prompt a protocol amendment.
• Screen failure volume feeds directly into recruitment planning and timeline forecasting: if a site or trial needs a given number of randomized participants and typically loses a known proportion at screening, the pre-screening funnel (referrals, pre-screens, formal screens) has to be sized accordingly. See clinical trial patient recruitment for how that funnel is built and monitored.
• Screen failures are also reported in the CONSORT-style participant flow diagram that accompanies trial publications and, for applicable trials, in the enrollment breakdown on ClinicalTrials.gov — a transparency practice that lets readers see how many people were assessed for eligibility versus how many were actually randomized, per the MRCT Center’s Clinical Research Glossary (Brigham and Women’s Hospital / Harvard).

Does a screen failure require IRB reporting?

A screen failure by itself — a participant simply not meeting eligibility criteria — is not an adverse event, an unanticipated problem, or a protocol deviation, and does not typically trigger a standalone IRB report. The screening process itself was already reviewed and approved by the IRB as part of the protocol and informed consent documents; a participant being screened out is that approved process functioning as designed, and it’s simply logged in the trial’s screening and enrollment records rather than reported as an event.

What does create a reporting obligation is anything that happens during the screening procedures themselves. Screening under an approved protocol and consent is still a regulated research activity — if a screening-phase procedure (a biopsy, an imaging study, a medication washout, a screening blood draw) causes an adverse event, or if screening was conducted outside what the IRB-approved protocol and consent actually authorized, that is reportable on its own terms under the site’s IRB and the trial’s safety reporting plan — the fact that the participant never reached randomization doesn’t exempt it. Sites should follow the specific reporting requirements in the protocol and their IRB’s written policy (see 21 CFR Part 56 for the US IRB framework and IRB/REC approval process for what gets reviewed and when) rather than assume a blanket rule either way.

Budget and participant payment treatment

Screen failures have real financial consequences that research administrators negotiate for explicitly, not incidentally:

• Site budget: the site incurs real cost for a screen failure — consent discussion, coordinator time, screening labs or imaging, IRB-approved procedures — even though the participant never proceeds to a billable study visit. Most clinical trial agreements negotiate a separate, typically reduced “screen failure fee” (or per-procedure reimbursement for screening-specific costs) distinct from the per-visit payment schedule that applies once a participant is randomized. See the cost of running a clinical trial for how this fits into overall site budgeting.
• Participant payment: many IRB-approved payment schedules provide the participant a modest, pro-rated payment or reimbursement for the screening visit itself (time and travel), separate from and typically smaller than the payment tied to study-intervention visits, so that a person isn’t penalized for attempting to participate in good faith. This is reviewed by the IRB as part of the consent/payment schedule to confirm it doesn’t function as undue inducement to enroll despite ineligibility. See clinical trial participant payments for how that structure and IRB review works.

Related concepts

Screen failure sits at the boundary between trial recruitment and formal enrollment, and touches eligibility design covered in designing a clinical trial, informed consent practice, and site financial operations. See the clinical research cluster overview for the broader operational landscape it belongs to.